Etoposide, vincristine, and cyclosporin a with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: A pediatric oncology group phase I study

Pediatric Blood and Cancer

Volumn 45, Issue 5, 2005, Pages 644-648

  Greenberg, Mark L ^a   Fisher, Paul G ^b   Freeman, Carolyn ^c   Korones, David N ^d   Bernstein, Mark ^e   Friedman, Henry ^f   Blaney, Susan ^g   Hershon, Linda ^e   Zhou, Tianni ^h   Chen, Zhenejia ^h   Kretschmar, Cynthia ⁱ  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g TEXAS CHILDREN S CANCER CENTER   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ TUFTS MEDICAL CENTER   (United States)

Author keywords

Brain stem; Chemoradiotherapy; Diffuse; Glioma; Pediactric

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; ETOPOSIDE; GLYCOPROTEIN P; VALSPODAR; VINCRISTINE;

ADOLESCENT; ANEMIA; ARTICLE; BLOOD BRAIN BARRIER; BRAIN STEM TUMOR; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMA; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DOSE RESPONSE; ENDOTHELIUM CELL; FEMALE; GLIOMA; HUMAN; ILEUS; JAW DISEASE; LIVER TOXICITY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; THROMBOCYTOPENIA; TUMOR NECROSIS; VOMITING; WHITE MATTER; XENOBIOTIC METABOLISM;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOSPORINE; DISEASE PROGRESSION; DOSE FRACTIONATION; ETOPOSIDE; GLIOMA; HUMANS; RADIOTHERAPY DOSAGE; VINCRISTINE;

EID: 24644518573     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20382     Document Type: Article

References (23)

1. Freeman CR, Krischer JP, Sanford RA, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brainstem tumors in children: A Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 1993;27:97-206.
2. Packer RJ, Boyett JM, Zimmerman RA, et al. Outcome of children with brainstem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Children's Cancer Group Phase I/II trial. Cancer 1994;74:1827-1834.
3. Prados MD, Wara WM, Edwards MS, et al. The treatment of brainstem and thalalmic gliomas with 78 Gy of hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:85-91.
4. Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and hitepa: A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 2000;88:685-692.
5. Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: Phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol 2002;20:3431-3437.
6. Kretschmar CS, Tarbell NJ, Barnes PD, et al. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brainstem tumors. A phase II study of the Pediatric Oncology Group, Protocol 8833. Cancer 1993;72:1404-1413.
7. Liu L, Vapiwala N, Munoz LK, et al. A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. Med Pediatr Oncol 2001;37:390-392.
8. Doz F, Neuenschwander S, Bouffet E, et al. Carboplatin before, and during radiation therapy for the treatment of malignant brainstem tumours: A study by the Societe Francaise d'Oncologie Pediatrique. Eur J Cancer 2002;38:815-819.
9. Packer RJ, Prados M, Phillips P, et al. Treatment of children with newly diagnosed brainstem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: A Children's Cancer Group phase I/II study. Cancer. 1996; 15; 77: 2150-2156.
10. Schinkel AH, Smit JJM, Van Tellingen O, et al. Disruption of the Mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
11. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-698.
12. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10:1635-1642.
13. Yahanda AM, Adler KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multi-drug resistance. J Clin Oncol 1992;10:1624-1634.
14. Chamberlain MC. Recurrent Brainstem gliomas treated with oral VP-16. J Neuro-oncology 1993;15:1323-1339.
15. Arboix M, Paz OG, Colombo T, et al. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J Pharmacol Exp Ther 1997;281:1226-1230.
16. Theis JG, Chan HS, Greenberg ML, et al. Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. Med Pediatr Oncol 2000;34:242-249.
17. Pace MT, Slovis TL, Kelly JK, et al. Cyclosporin toxicity: MRI appearance of the brain. Pediatr Radiol 1995;25:180-183.
18. Gulbis B, Van der Heiden J, Van As H, et al. Whole blood cyclosporine monitoring in liver and heart transplant patients: Evaluation of the specificity of a fluorescence polarization immunoassay and an enzyme-multiplied immunoassay technique. J Pharm Biomed Anal 1997;15:957-963.
19. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
20. Appignani BA, Bhadelia RA, Blacklow SC, et al. Neuroimaging findings in patients on immunosuppressive therapy. Am J Roentgenol 1996;166:683-688.
21. Cowie F, Pinkerton CR. Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance (letter). J Clin Oncol 1994;12:1998-1999.
22. Bates S, Kang M, Meadows B, et al. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer. 2001;92:1577-1590.
23. Weber DM, Dimopoulos MA, et al. Increased neurotoxicity with VAD cyclosporin in multiple myeloma (letter, comment). Lancet 1993;341:558-559.